Login / Signup

Remission of Proteinuria May Protect against Progression to Chronic Kidney Disease in Pediatric-Onset IgA Nephropathy.

Jin-Soon SuhKyung Mi JangHyesun HyunMyung Hyun ChoJoo Hoon LeeYoung Seo ParkJae Hyuk OhJi Hong KimKee Hwan YooWoo Yeong ChungSeong Heon KimKeehyuck KimDae Yeol LeeJung Won LeeMin Hyun ChoHyewon ParkJa Wook KooKyoung Hee HanEun Mi YangKeum Hwa LeeYoun Ho ShinHeeyeon ChoKyo Soon KimIl-Soo HaYong Hoon ParkHee Gyung Kang
Published in: Journal of clinical medicine (2020)
Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerulopathies diagnosed in children and adolescents. This study aimed to evaluate the clinical features in and outcomes of pediatric IgAN over the last 30 years. Patients who were diagnosed before age of 18 at 20 centers in Korea were evaluated retrospectively. Of the 1154 patients (768 males, 386 females) with a median follow-up of 5 years, 5.6% (n = 65) progressed to stage 3-5 chronic kidney disease (CKD). The 10- and 20-year CKD-free survival rates were 91.2% and 75.6%, respectively. Outcomes did not differ when comparing those in Korea who were diagnosed prior to versus after the year 2000. On multivariate analysis, combined asymptomatic hematuria and proteinuria as presenting symptoms and decreased renal function at the time of biopsy were associated with progression to CKD, while remission of proteinuria was negatively associated with this outcome. Patients who presented with gross hematuria or nephrotic syndrome tended toward positive outcomes, especially if they ultimately achieved remission. While remission of proteinuria might imply that the disease is inherently less aggressive, it also can be achieved by management. Therefore, more aggressive management might be required for pediatric-onset IgAN.
Keyphrases
  • chronic kidney disease
  • end stage renal disease
  • disease activity
  • free survival
  • peritoneal dialysis
  • systemic lupus erythematosus
  • type diabetes
  • case report